Breaking News

QPharma Appoints DEA Director

By Kristin Brooks | March 19, 2014

Crusan brings extensive compliance experience

Matt Crusan has been appointed director of DEA Compliance and Services at QPharma. Mr. Crusan has served as a diversion investigator with the Drug Enforcement Administration (DEA), and brings extensive knowledge of DEA regulatory policy to QPharma’s newly established DEA compliance practice.
 
Mr. Crusan joins the company from the Pharma Compliance Group, where he served as director of regulatory affairs providing DEA compliance consulting services to manufacturers, distributors, hospitals, and retail pharmacy chains. Mr. Crusan also has experience conducting enterprise-wide DEA gap analyses and development of Suspicious Order & Monitoring (SOM) programs for drug wholesalers and manufacturers.
 
The new DEA compliance practice will include offerings including mock DEA audits and inspections, due diligence/diversion analysis, Standard Operating Procedure review, and physician risk analysis.
 
“Matt’s outstanding credentials and breadth of experience speak for themselves,” said QPharma president and chief executive officer Patrick P. Den Boer. “We are pleased to welcome him to our Professional Services team.”
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.